Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ailitong ointment plus Oxycontin for cancer pain: mechanism and gene polymorphism study
ChiCTR2200058515Phase 4Not yet recruiting
- Sponsor
- Foshan Hospital of Traditional Chinese Medicine
- Start
- Apr 2022
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4 trial of oxycodone and Ailitong ointment in cancer pain (2 arms), sponsored by Foshan Hospital of Traditional Chinese Medicine. Primary endpoints: Genes of primary tumor, Gene CYP2D6 and 2 more. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
oxycodoneAilitong ointment
03
Conditions
cancer pain
Beyond the preview
Go deeper on ChiCTR2200058515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058515.